AbbVie (NASDAQ: ABBV) is expected to report first-quarter 2026 results on April 29. The company anticipates neuroscience revenues of approximately $2.8 billion, with the Zacks Consensus Estimate at $2.79 billion, reflecting an estimated 22% year-over-year growth. Key drivers for this growth include strong sales of Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, alongside contributions from the recently launched Parkinson’s disease therapy, Vyalev.
AbbVie’s neuroscience segment has become increasingly vital for revenue, helping offset declines from older therapies. In contrast, the company faces competition from Biogen and Johnson & Johnson in the neuroscience market, where both companies are diversifying their product offerings.
Currently, AbbVie shares trade at a price-to-earnings (P/E) ratio of 14.15, below the industry average of 17.18. Earnings per share estimates for 2026 and 2027 have declined over the past month, reflecting challenges in the broader market.
